Have a feature idea you'd love to see implemented?
Let us know!
CGON Cg Oncology Inc.
Price (delayed)
$32.34
Market cap
$2.19B
P/E Ratio
N/A
Dividend/share
N/A
EPS
-$5.3
Enterprise value
$2.14B
We are a late-stage clinical biopharmaceutical company focused on developing and commercializing a potential backbone bladder-sparing therapeutic for patients afflicted with bladder cancer. Our product candidate, cretostimogene, is initially in
Highlights
CGON's EPS has soared by 63% YoY and by 41% from the previous quarter
Cg Oncology's debt has decreased by 43% YoY and by 17% QoQ
The quick ratio has soared by 99% YoY but it has contracted by 26% from the previous quarter
Cg Oncology's net income has shrunk by 79% YoY and by 14% QoQ
CGON's equity is down by 2.8% since the previous quarter
Key stats
What are the main financial stats of CGON
Market
Valuations
Earnings
Shares outstanding
67.63M
Market cap
$2.19B
Enterprise value
$2.14B
Price to earnings (P/E)
N/A
Price to book (P/B)
4.04
Price to sales (P/S)
3,174.6
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
3,134.54
Revenue
$684,000
EBIT
-$75.18M
EBITDA
-$75.16M
Free cash flow
-$74.14M
Per share
Balance sheet
Liquidity
EPS
-$5.3
Free cash flow per share
-$1.1
Book value per share
$8
Revenue per share
$0.01
TBVPS
$8.23
Total assets
$552.47M
Total liabilities
$15.7M
Debt
$296,000
Equity
$536.77M
Working capital
$536.45M
Debt to equity
0
Current ratio
35.32
Quick ratio
34.6
Net debt/EBITDA
0.57
Margins
Efficiency
Dividend
EBITDA margin
-10,988%
Gross margin
100%
Net margin
-10,578.2%
Operating margin
-13,969.2%
Return on assets
-16.5%
Return on equity
-20.4%
Return on invested capital
-17.8%
Return on capital employed
-14%
Return on sales
-10,990.5%
Dividend yield
N/A
DPS
N/A
Payout ratio
N/A
CGON stock price
How has the Cg Oncology stock price performed over time
Intraday
0.31%
1 week
-8.9%
1 month
-11.9%
1 year
N/A
YTD
N/A
QTD
-14.29%
Financial performance
How have Cg Oncology's revenue and profit performed over time
Revenue
$684,000
Gross profit
$684,000
Operating income
-$95.55M
Net income
-$72.36M
Gross margin
100%
Net margin
-10,578.2%
The operating income has dropped by 110% year-on-year and by 18% since the previous quarter
Cg Oncology's net income has shrunk by 79% YoY and by 14% QoQ
Cg Oncology's net margin has increased by 47% YoY but it has decreased by 8% QoQ
Cg Oncology's operating margin has increased by 38% YoY but it has decreased by 12% QoQ
Growth
What is Cg Oncology's growth rate over time
Valuation
What is Cg Oncology stock price valuation
P/E
N/A
P/B
4.04
P/S
3,174.6
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
3,134.54
CGON's EPS has soared by 63% YoY and by 41% from the previous quarter
CGON's equity is down by 2.8% since the previous quarter
CGON's revenue is up by 5% since the previous quarter
Efficiency
How efficient is Cg Oncology business performance
CGON's ROS is up by 46% YoY but it is down by 7% from the previous quarter
The ROE has increased by 40% since the previous quarter
The company's return on assets rose by 39% YoY and by 15% QoQ
Cg Oncology's return on invested capital has increased by 18% YoY and by 7% QoQ
Dividends
What is CGON's dividend
DPS
N/A
Dividend yield
N/A
Payout ratio
N/A
There are no recent dividends present for CGON.
Financial health
How did Cg Oncology financials performed over time
Cg Oncology's total assets has soared by 161% YoY but it has decreased by 2.1% from the previous quarter
The quick ratio has soared by 99% YoY but it has contracted by 26% from the previous quarter
Cg Oncology's debt is 100% lower than its equity
Cg Oncology's debt has decreased by 43% YoY and by 17% QoQ
CGON's equity is down by 2.8% since the previous quarter
All financial data is based on trailing twelve months (TTM) periods - updated quarterly, unless otherwise
specified. Data from 
and Sharadar.